Indication
As monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
Medicine details
- Medicine name:
- zanubrutinib (Brukinsa)
- SMC ID:
- SMC2684
- Pharmaceutical company
- BeiGene UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 11 November 2024
- SMC meeting date:
- 01 October 2024
- Patient group submission deadline:
- 06 August 2024